Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3925187 | 0.83 | ESR1 (1.00) | ESR2ESR1 | |
| SCHEMBL5981042 | 0.83 | ESR2 (0.70) | ESR2ESR1 | |
| SCHEMBL3926540 | 0.80 | ESR1 (1.00) | ESR2ESR1 | |
| SCHEMBL15892259 | 0.77 | ESR1 (0.65) | ESR2ESR1 | |
| SCHEMBL3922949 | 0.76 | ESR1 (0.60) | ESR2ESR1 | |
| SCHEMBL3933824 | 0.75 | ESR1 (1.00) | ESR2ESR1 | |
| SCHEMBL10539436 | 0.75 | AHR (0.65) | ESR2ESR1 | |
| SCHEMBL11608660 | 0.73 | ESR2 (0.72) | ESR2ESR1 | |
| SCHEMBL2399696 | 0.73 | ESR2 (0.72) | ESR2ESR1 | |
| SCHEMBL8677567 | 0.73 | ESR2 (0.72) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | claimed |
| US-20060135574-A1 | Novel uses for estrogen beta agonists | WYETH (US) | 2006-06-22 | — | — | US | claimed |
| CN-1738788-A | Substituted phenylnaphthalenes as estrogenic agents | WYETH CORP (US) | 2006-02-22 | — | — | CN | claimed |
| US-6914074-B2 | Substituted phenyl naphthalenes as estrogenic agents | WYETH (US) | 2005-07-05 | — | — | US | claimed |
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | WYETH | 2003-09-25 | — | — | US | claimed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | disclosed |
| US-7067524-B2 | Substituted phenyl naphthalenes as estrogenic agents | WYETH (US) | 2006-06-27 | — | — | US | disclosed |
| US-20060135574-A1 | Novel uses for estrogen beta agonists | WYETH (US) | 2006-06-22 | — | — | US | disclosed |
| CN-1738788-A | Substituted phenylnaphthalenes as estrogenic agents | WYETH CORP (US) | 2006-02-22 | — | — | CN | disclosed |
| US-6914074-B2 | Substituted phenyl naphthalenes as estrogenic agents | WYETH (US) | 2005-07-05 | — | — | US | disclosed |
| US-20040225123-A1 | Substituted phenyl naphthalenes as estrogenic agents | MEWSHAW RICHARD E (US) | 2004-11-11 | — | — | US | disclosed |
| EP-1453782-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | WYETH | 2003-09-25 | — | — | US | disclosed |
| WO-2003051805-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | ESR2, ESR1, ESRRA | ESR2 1/4885ESR1 2/4885 |
| US-20060135574-A1 | Novel uses for estrogen beta agonists | GPER1, ESR2, ESR1 | ESR2 2/4885ESR1 3/4885 |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | COL2A1, COL1A1, COL14A1 | ESR2 5/4885ESR1 4/4885 |
| US-20040225123-A1 | Substituted phenyl naphthalenes as estrogenic agents | ESR2, ESR1, ESRRA | ESR2 1/4885ESR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.